Wegovy vs Ozempic: The Real Difference, Explained by a Chattanooga MD
I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.
Patients in Chattanooga ask me this almost every week, usually before they’ve said anything else: what is the actual difference between Wegovy and Ozempic? I’m Dr. Paul Miranda, board-certified in family medicine, and I built Summit Metabolic Health here to answer that kind of question honestly instead of routing you to a checkout page. The short version: there isn’t a chemical difference. There’s a dose difference, a labeling difference, and an insurance system that treats those two differences like they’re everything.
Both pens contain semaglutide. Same molecule, same mechanism, made by the same manufacturer. What changes between the two products is the maximum dose on the label and what the FDA approved that dose to treat. Ozempic tops out at 2 mg weekly and is approved for type 2 diabetes. Wegovy goes up to 2.4 mg weekly and is approved for chronic weight management. That’s it. There is no separate “weight loss version” of semaglutide invented in a different lab — it’s the same drug, titrated higher and stamped with a different purpose.
I understand why this feels like a trick. The commercials run on different channels, use different colors, and never mention they’re the same active ingredient. But read the prescribing information for either one and the molecule listed is identical: semaglutide. The dose and the indication are the only things that separate them.
The FDA doesn’t approve a drug — it approves a drug for a specific use, at a specific dose, based on the trials the manufacturer actually ran for that use. Novo Nordisk ran its diabetes trials at doses up to 2 mg and got Ozempic approved for diabetes. It ran a separate set of trials at doses up to 2.4 mg specifically for weight loss, and that program produced Wegovy’s approval for chronic weight management.
This is a regulatory distinction, not a pharmacological one. A physician can legally prescribe Ozempic off-label for weight loss at a lower dose, and plenty do. But the FDA label only covers what was actually studied and submitted for that specific product — which is why the two drugs live under different names and different coverage rules despite being the same compound.
The trial that got Wegovy approved for weight loss is called STEP 1 (Wilding et al., NEJM, 2021). Patients on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% on placebo. That’s the actual number behind the marketing — a real, substantial average, and also a group average from a clinical trial, not a promise about what any one patient will see.
The second trial matters regardless of which bottle is in your hand. SELECT (Lincoff et al., NEJM, 2023) looked at semaglutide’s effect on cardiovascular events in people with existing heart disease and found a 20% reduction in major adverse cardiac events — heart attack, stroke, cardiovascular death. That benefit tracked the drug, not the brand. A patient on Ozempic for diabetes and a patient on Wegovy for weight loss are both on the molecule SELECT studied. I work ER shifts, and heart attacks from untreated metabolic disease are not abstract to me. That cardiovascular data is a big part of why I take this medication seriously regardless of which label is on the box.
Insurance in this country pays based on diagnosis codes attached to an FDA-approved indication, not based on the drug itself. A diabetes diagnosis plus an Ozempic prescription usually clears the formulary without much fight, because insurers have decades of actuarial data on treating diabetes. A weight-loss diagnosis plus a Wegovy prescription routes into a completely different, far stingier set of rules — many employer plans explicitly carve out obesity medications regardless of medical necessity, calling it a “lifestyle” exclusion rather than a medical one.
So the same molecule, at a slightly higher dose, for a condition insurers have decided to treat as optional, gets denied far more often than the lower dose treating a condition they’ve decided to treat as medical. That’s not a judgment on your biology. It’s a line item on a spreadsheet. I’ve written about this gap in detail — what Tennessee plans actually cover and what they don’t — in the breakdown on semaglutide coverage in Tennessee, and the same denial logic shows up again in the Chattanooga-specific look at Wegovy vs. Ozempic I wrote a few weeks before this one.
This is the part that actually changes what a patient does next. Compounded semaglutide, prescribed and dosed by a physician outside the brand-name insurance pathway, uses the same active ingredient and the same mechanism of action as both Wegovy and Ozempic. It sidesteps the entire insurance fight because it isn’t billed through insurance at all — it’s a self-pay prescription, dosed and titrated by the prescribing physician rather than fixed to a manufacturer’s dose ladder.
At Summit, that runs $175–249 a month, with every dose change and every chart reviewed by me personally — not a nurse queue, not a questionnaire run through software. Compare that to the post-discount-cliff pricing at direct-to-consumer telehealth platforms like Hims or Ro, which lands at $398–548 a month once the introductory rate expires. Same mechanism either way. The difference is the dosing philosophy behind it and who’s actually reading the chart. I go into the cost math in more depth in the compounded semaglutide vs. Ozempic cost comparison, and the full catalog of pieces like it lives on the Summit Metabolic Health blog.
One honest caveat: compounded semaglutide is not FDA-approved as its own product, and it is not identical to the brand-name version in a regulatory sense — it’s the same active ingredient, compounded under a physician’s prescription rather than manufactured and packaged by Novo Nordisk. That distinction matters, and any clinic that tells you otherwise isn’t being straight with you.
None of this — the dose, the label, the insurance code, the cost — should get decided by a checkout flow. A board-certified physician needs to see your history, your other medications, and your actual metabolic picture before deciding where to start you and how fast to move the dose. I’ve watched what happens in the ER when someone self-manages a GLP-1 medication with no one checking in: it’s preventable, and it’s exactly why I review every chart at Summit myself instead of handing that decision to a form.
You can buy semaglutide from a lot of places now, under a lot of names. What’s harder to find is a Chattanooga physician who explains the actual difference between Wegovy and Ozempic instead of selling you whichever one converts better, then sits with you through every dose change until you’re at a number you can hold.
Ready to start? Apply at summitmetabolichealth.com/apply.
This article is for informational purposes and does not replace a one-on-one medical evaluation. Individual results vary; the trial outcomes cited above are group averages, not a guarantee for any specific patient.
